Stockscreener 앱 받기
51.43
2.82%
1.41
Gsk Plc Adr 주식(GSK)의 최신 뉴스
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Zacks Investment Research
Can Expanding Ivonescimab Development Unlock SMMT's Growth Potential? - Zacks Investment Research
Analysts Estimate GSK (GSK) to Report a Decline in Earnings: What to Look Out for - Zacks Investment Research
Metabolic Dysfunction-Associated Steatohepatitis Clinical Trial and Competitive Landscape Expands as 180+ Companies Target New Treatment Options | DelveInsight - GlobeNewswire Inc.
HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China - GlobeNewswire Inc.
GSK's New Drugs and Pipeline Hold the Key to Long-Term Growth - Zacks Investment Research
Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer - GlobeNewswire Inc.
GSK plc (GSK) Stock Climbs 2.40% to $49.02, Positioned Evenly Between Support and ResistanceEarnings Beat Stocks - dars.gov.et
GSK plc (GSK) Stock Climbs 2.40% to $49.02, Positioned Evenly Between Support and ResistanceWave Alternation - https://www.siam.in/
Could Investing $5,000 in D-Wave Quantum Stock Today Make You a Millionaire? - The Motley Fool
At £17.3550 per ordinary share, dividend reinvestment adds to GSK (GSK) executives’ interests. - Stock Titan
Prediction: These 3 Dividend Stocks Will Raise Their Payouts No Matter What the Market Does - The Motley Fool
MRNA Stock Gains Over $4B in a Week: Time to Buy, Hold or Sell? - Zacks Investment Research
Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Dividend reinvestment brings GSK (NYSE: GSK) CEO Luke Miels 23.331 ordinary shares. - Stock Titan
Complicated Urinary Tract Infections Market Set for Expansion by 2036, Supported by Recent Drug Approvals Including GSK/Spero Therapeutics’ UTEBZI and Wockhardt’s ZAYNICH and Emerging Therapies | DelveInsight - GlobeNewswire Inc.
SGIOY Stock Price, Quote & News - Syfe
Hatteras Venture Partners Names Sir Andrew Witty as Chairman and Ned Sharpless, M.D., as Managing Director of Hatteras Discovery Innovation, Expanding Proven Investment Strategies - GlobeNewswire Inc.
GSK vs. SNY: Which Europe-Based Pharma Stock Has More Potential? - Zacks Investment Research
HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors - GlobeNewswire Inc.
Form 13D/A Opera Limited For: 24 September By Investing.com - Investing.com UK
GSK (NYSE: GSK) board members are buying company stock - Stock Titan
Renalytix rises 7% as UBS holding grows and CEO buys shares - Yahoo Finance UK
GSK's Specialty Medicines Drive Growth Amid Looming HIV Patent Cliff - Zacks Investment Research
Monoclonal Antibodies Market to Grow at 11.01% CAGR, Reaching USD 791.28 Billion by 2035 – SNS Insider - GlobeNewswire Inc.
GSK plc (GSK) stock price, news, quote and history - Yahoo Finance Australia
Drug Repurposing Market to Reach USD 50.91 Billion by 2035, Expanding at 3.93% CAGR | SNS Insider - GlobeNewswire Inc.
Zacks Investment Research - גלובס
GSK Stock Down 14% in Six Months: Time to Buy, Hold or Exit? - TradingView
GSK stock holds steady as investors weigh recent earnings and dividend - ad-hoc-news.de
BNTX Stock Price, Quote & News - Syfe
Measles Kills 2 in Pennsylvania: What Do Prediction Markets Say About the Disease? - sahmcapital.com
GSK (GSK) Results Breakdown: The Available Earnings Metric Delivers a Beat in the Latest Session; Post-Earnings: Shares Move Lower 1.20% in Latest TradingGrowth Acceleration Report - careplusvn.com
GSK (GSK) Results Breakdown: The Available Earnings Metric Delivers a Beat in the Latest Session; Post-Earnings: Shares Move Lower 1.20% in Latest TradingEarnings Decline Risk - dars.gov.et
GSK (GSK) Results Breakdown: The Available Earnings Metric Delivers a Beat in the Latest Session; Post-Earnings: Shares Move Lower 1.20% in Latest TradingOne-Time Gain Impact - www.dars.gov.et
Resilient GSK stock holds firm as FDA and Japan clear key drugs - ad-hoc-news.de
Resilient GSK stock steadies after recent earnings beat and sector scrutiny - ad-hoc-news.de
ETFs Investing in GSK plc Sponsored ADR Stocks - TradingView
GSK (GSK) Q2 2026 Earnings: The Bottom-Line Figure Beats Its Comparison on the Day; Price Move: Shares Fall 1.74% on the DayProfit Cycle Analysis - careplusvn.com
GSK (GSK) Q2 2026 Earnings: The Bottom-Line Figure Beats Its Comparison on the Day; Price Move: Shares Fall 1.74% on the DayRevenue Breakdown Analysis - dars.gov.et
GSK (GSK) Q2 2026 Earnings: The Bottom-Line Figure Beats Its Comparison on the Day; Price Move: Shares Fall 1.74% on the DayEarnings Power Value - dars.gov.et
GSK (GSK) Q2 2026 Earnings: The Bottom-Line Figure Beats Its Comparison on the Day; Price Move: Shares Fall 1.74% on the DayCEO Earnings Statement - https://www.dars.gov.et/
GSK (GSK) Latest: Ends Higher by 2.35% at $52.35 at the Close; Market Levels: $49.73 and $54.97 Define the Nearby Reference Levels at the CloseVolume Weighted Price - careplusvn.com
GSK (GSK) Snapshot: Finishes 2.40% Higher at $52.38 on the Day; Chart Watch: $49.76 and $55.00 Define the Nearby Reference Levels in the Current UpdateMoney Flow - www.dars.gov.et
GSK (GSK) Snapshot: Finishes 2.40% Higher at $52.38 on the Day; Chart Watch: $49.76 and $55.00 Define the Nearby Reference Levels in the Current UpdateConversion Trade - dars.gov.et
GSK (GSK) Snapshot: Finishes 2.40% Higher at $52.38 on the Day; Chart Watch: $49.76 and $55.00 Define the Nearby Reference Levels in the Current UpdateDealer Positioning - dars.gov.et
GSK Set up for Steady Long-Term Growth As Portfolio and Pipeline Develop - Morningstar
Inside ARMH, STHH and ASMH: Three Semiconductor ADRhedged™ ETFs, and What the Currency Hedge Actually Added - TipRanks
Funding Roundup: Silence Therapeutics, AbCellera Announce IPO Pricing, Beyang, Remepy Close Series A Financing - Pharmaceutical Executive
Silence Therapeutics Plans Underwriters' Option: Up to 15% More Depositary Shares - Stock Titan
2.67%
자본화:
|
볼륨(24시간):